Determining the Clearance of Degraded Protein via a Monoclonal Antibody Purification Process in Support of Cleaning Carryover Limits in Multiproduct Facilities

References

1. 1.↵
   Parenteral Drug Association Inc. Technical Report No. 29: Points to Consider for Cleaning Validation (Revised 2012); Bethesda, MD, 2012.
2. 2.↵
   Parenteral Drug Association Inc. Technical Report No. 49: Points to Consider for Biotechnology Cleaning Validation; Bethesda, MD, 2010.
3. 3.↵
   International Conference on Harmonisation, ICH Harmonised Tripartate Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. ICH Geneva, 2000.
4. 4.↵
   1. Liu H. F.,
   2. Ma J.,
   3. Winter C.,
   4. Bayer R.

   Recovery and Purification Process Development for Monoclonal Antibody Production. MAbs 2010, 2 (5), 480–499.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Fahrner R. L.,
   2. Knudsen H. L.,
   3. Basey C. D.,
   4. Galan W.,
   5. Feuerhelm D.,
   6. Vanderlaan M.,
   7. Blank G. S.

   Industrial Purification of Pharmaceutical Antibodies: development, Operation, and Validation of Chromatography Processes. Biotechnol. Genet. Eng. Rev. 2001, 18 (1), 301–327.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Mehta A.,
   2. Tse M. L.,
   3. Fogle J.,
   4. Len A.,
   5. Shrestha R.,
   6. Fontes N.,
   7. Lebreton B.,
   8. Wolk B.,
   9. van Reis R.

   Purifying Therapeutic Monoclonal Antibodies. Chem. Eng. Prog. 2008, 104 (5), S14–S20.

   OpenUrl
7. 7.↵
   1. Shukla A. A.,
   2. Hubbard B.,
   3. Tressel T.,
   4. Guhan S.,
   5. Low D.

   Downstream Processing of Monoclonal Antibodies–Application of Platform Approaches. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2007, 848 (1), 28–39.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Curtis S.,
   2. Lee K.,
   3. Blank G. S.,
   4. Brorson K.,
   5. Xu Y.

   Generic/Matrix Evaluation of SV40 Clearance by Anion Exchange Chromatography in Flow-through Mode. Biotechnol. Bioeng. 2003, 84 (2), 179–186.

   OpenUrlPubMed
9. 9.↵
   1. Norling L.,
   2. Lute S.,
   3. Emery R.,
   4. Khuu W.,
   5. Voisard M.,
   6. Xu Y.,
   7. Chen Q.,
   8. Blank G.,
   9. Brorson K.

   Impact of Multiple Re-Use of Anion-Exchange Chromatography Media on Virus Removal. J. Chromatogr. A 2005, 1069 (1), 79–89.

   OpenUrlPubMed
10. 10.↵
    1. Strauss D. M.,
    2. Gorrell J.,
    3. Plancarte M.,
    4. Blank G. S.,
    5. Chen Q.,
    6. Yang B.

    Anion Exchange Chromatography Provides a Robust, Predictable Process to Ensure Viral Safety of Biotechnology Products. Biotechnol. Bioeng. 2009, 102 (1), 168–175.

    OpenUrlPubMed
11. 11.↵
    1. Kendrik K.,
    2. Canhoto A.,
    3. Kreuze M.

    Analysis of Degradation Properties of Biopharmaceutical Active Ingredients as Caused by Various Process Cleaning Agents and Temperature. J. Valid. Technol. 2009, 15 (3), 69–77.

    OpenUrl
12. 12.↵
    1. Vlasak J.,
    2. Ionescu R.

    Fragmentation of Monoclonal Antibodies. MAbs 2011, 3 (3), 253–263.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Mott A.,
    2. Henry B.,
    3. Wyman E.,
    4. Bellorado K.,
    5. Blümel M.,
    6. Parks M.,
    7. Hayes R.,
    8. Runkle S.,
    9. Luo W.

    Methodology for Assessing Product Inactivation during Cleaning. Part II: Setting Acceptance Limits of Biopharmaceutical Product Carryover for Equipment Cleaning. J. Valid. Technol. 2013, 19 (4), 1–8.

    OpenUrl
14. 14.↵
    1. LeBlanc D.

    Issues in Setting Limits for Actives in Bulk Biotech Manufacture. J. Valid. Technol. 2009, 15 (1), 71–76.

    OpenUrl